MIT LNP Technique: Organ-specific RNA delivery method explained

MIT News USA

Overview

MIT researchers have developed a novel lipid nanoparticle (LNP) manufacturing technique that precisely controls particle size and shape, critical for targeted RNA drug delivery. This innovation significantly enhances LNP biodistribution, overcoming previous challenges in directing RNA therapies to specific organs beyond the liver. The technology is patented and being commercialized through BIZON Labs, promising to accelerate the development and broaden the therapeutic scope of RNA-based medicines.

In Depth

Key Findings

Researchers at the Massachusetts Institute of Technology (MIT) have unveiled a groundbreaking manufacturing technique for lipid nanoparticles (LNPs), which are critical delivery vehicles for RNA therapeutics. This new method enables unprecedented control over the size and shape of LNPs, directly impacting their biodistribution and allowing for significantly improved targeted delivery of RNA drugs to specific organs and tissues within the body. This advance is paramount for enhancing the efficacy and safety profiles of a wide range of RNA-based therapies.

Technical / Clinical Details

The developed manufacturing process leverages advanced microfluidics to precisely govern the LNP formation kinetics. This control ensures the generation of highly uniform particles in terms of both size and morphology. Historically, variability in LNP batches and off-target accumulation in non-diseased organs have been significant hurdles. The MIT technique addresses these limitations by optimizing LNP characteristics to extend circulation time and reduce undesirable clearance, thus enabling more specific and efficient targeting. For instance, by controlling particle attributes like lipid chemistry, ratio, morphology, and surface charge, the researchers can engineer LNPs to preferentially accumulate in desired tissues rather than being predominantly absorbed by the liver.

Background & Context

LNPs gained prominence as the delivery system for highly successful mRNA COVID-19 vaccines. However, current LNP technologies are largely optimized for hepatic delivery. Expanding RNA therapeutics to treat diseases in extrahepatic organs such as the brain, lungs, or muscles has been a major challenge in drug development. This MIT innovation offers a promising solution by providing the tools to tailor LNP properties for specific anatomical targets, thus unlocking a new frontier for genetic medicines.

Strategic Significance & Outlook

The research team has filed for a patent on this technology and is commercializing it through a new spin-off company, BIZON Labs. The ability to finely tune LNP characteristics for organ-specific targeting is expected to accelerate the development of next-generation RNA therapeutics for various diseases, including those previously intractable due to delivery limitations. This advancement holds immense potential to revolutionize gene therapy, oncology, and other therapeutic areas by enabling more effective and safer delivery of genetic medicines, pushing beyond the current liver-centric targeting paradigm.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime